In mice made obese by diet, a combination of two drugs called bimagrumab and semaglutide increases their maximum oxygen uptake during exercise by about 13% compared to untreated mice, and this improvement is linked to an increase in muscle mass.
See the scientific wording
In diet-induced obese mice, combination treatment with bimagrumab and semaglutide increases VO2 max by approximately 13% compared to control mice, and this increase is dependent on an increase in lean mass.
Correlational — new studies may shift this
Randomized trialsOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyAnimal2024
When obese mice got both drugs, they kept their muscle and lost more fat, and they could run 13% better — and the scientists say it was because of the extra muscle, not because the drugs directly improved their heart or lungs.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Blocking a specific muscle signal stops muscle breakdown and makes muscles grow bigger, while also helping the body burn fat more efficiently. Bigger muscles require more oxygen to work, so the body gets better at using oxygen during exercise, which lets the animal run longer and harder.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In mice made obese by diet, a combination of two drugs called bimagrumab and semaglutide increases their maximum oxygen uptake during exercise by about 13% compared to untreated mice, and this improvement is linked to an increase in muscle mass.
Mechanism
1 studyBlocking a muscle signal makes muscles grow bigger, and a second drug helps the body burn fat. Bigger muscles need more oxygen to work, so the body gets better at using oxygen during exercise, which lets the animal run farther and faster.
Blocking a specific muscle signal stops muscle breakdown and makes muscles grow bigger, while also helping the body burn fat more efficiently. Bigger muscles require more oxygen to work, so the body gets better at using oxygen during exercise, which lets the animal run longer and harder.
Bimagrumab binds to and blocks activin type II receptors on skeletal muscle cells
Blockade of activin type II receptors reduces Smad2/3 signaling, relieving suppression of muscle growth pathways
Alternative anabolic pathways, independent of Akt, increase protein synthesis and reduce protein breakdown in muscle fibers
Net accumulation of muscle protein increases skeletal muscle mass and fiber size
Semaglutide activates GLP-1 receptors, reducing food intake and increasing energy expenditure
Muscle hypertrophy alters systemic metabolic signaling, enhancing lipolysis and reducing adipocyte lipid storage
Adipose tissue mass decreases, adipocyte size shrinks, and inflammatory markers decline while adiponectin rises
Circulating glycerol and free fatty acids decrease as lipid mobilization and oxidation increase
Increased lean mass elevates total metabolic demand during physical activity
Higher metabolic demand drives improved oxygen extraction and utilization, increasing VO2 max
Evidence from Studies
Supporting (1)
Community contributions welcome
When obese mice got both drugs, they kept their muscle and lost more fat, and they could run 13% better — and the scientists say it was because of the extra muscle, not because the drugs directly improved their heart or lungs.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab and Semaglutide Combination Therapy on VO2 Max and Lean Mass in Diet-Induced Obese Mouse Models
Systematic review and meta-analysis of all peer-reviewed studies in diet-induced obese mice comparing combination treatment with bimagrumab and semaglutide versus control, measuring VO2 max, lean mass, and statistical dependency between lean mass change and VO2 max improvement.
Double-Blind Randomized Trial of Bimagrumab and Semaglutide Combination vs Placebo on VO2 Max and Lean Mass in Diet-Induced Obese Mice
Randomized, double-blind, placebo-controlled trial in diet-induced obese mice (n≥30 per group) receiving bimagrumab and semaglutide combination, single-agent treatments, or placebo, with VO2 max measured via treadmill testing and lean mass quantified by DEXA or MRI after 8–12 weeks of treatment.
Longitudinal Cohort Study of VO2 Max and Lean Mass Trajectories in Diet-Induced Obese Mice Treated with Bimagrumab and Semaglutide
Prospective cohort of diet-induced obese mice treated with bimagrumab and semaglutide, with serial measurements of lean mass and VO2 max at baseline, 4, 8, and 12 weeks, and statistical analysis of the temporal relationship between lean mass gain and VO2 max improvement.
In Vitro Analysis of Bimagrumab and Semaglutide Effects on Skeletal Muscle Cell Hypertrophy and Mitochondrial Function
Primary mouse skeletal muscle cell cultures treated with bimagrumab, semaglutide, or combination, measuring myotube diameter, protein synthesis rates, and mitochondrial respiration (Seahorse assay) over 72 hours.
Single-Arm Pilot Study of Bimagrumab and Semaglutide on VO2 Max and Body Composition in Diet-Induced Obese Mice
Non-randomized, single-group study in diet-induced obese mice (n=10) treated with bimagrumab and semaglutide for 12 weeks, measuring VO2 max and lean mass pre- and post-treatment without a control group.